In Phase C, contributors will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disorder progression or maybe the contributors are not able to tolerate the study drugs. Ubiquitin-linked proteins that regulate the stability of important Tremendous enhancer-mediated proteins https://adamm887cny1.popup-blog.com/profile